RemeGen Co., Ltd.
REGMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.58B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.58 Billion |
|---|---|
| Enterprise Value | $4.59 Billion |
| Earnings per Share | $1.26 |
| Beta | 0.45 |
| Outstanding Shares | 560,164,434 |
Return
| Return on Equity | 69.54% |
|---|---|
| Return on Assets | 58.71% |
| Return on Invested Capital | 57.23% |
Valuation & Multiples
| P/E Ratio | 9.74 |
|---|---|
| PEG | -0.42 |
| Price to Sales | 0.71 |
| Price to Book Ratio | 0.71 |
| Enterprise Value to Revenue | 0.58 |
| Enterprise Value to EBIT | 0.95 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$395.33 M
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About RemeGen Co. Ltd. Class A
3,048 employees
CEO: Jian Min Fang
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company of...